PulseAugur
EN
LIVE 19:59:54
中文(ZH) 中信建投：解锁不可成药靶点，RAS药物打开肿瘤治疗新格局

RAS-targeted therapies show promise for new cancer treatments

By PulseAugur Editorial · [1 sources] ·

CITIC Securities has released a research report highlighting the potential of RAS-targeted therapies in oncology. These therapies aim to unlock previously undruggable targets within the RAS gene family, which includes KRAS, NRAS, and HRAS, with KRAS being particularly significant in human cancers. The field is advancing beyond single-point mutations like KRAS G12C to address broader targets such as G12D, Pan-KRAS, and Pan-RAS(ON), with numerous companies actively pursuing these avenues. AI

RANK_REASON Research report from a financial institution detailing advancements in cancer therapy targets. [lever_c_demoted from research: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

RAS-targeted therapies show promise for new cancer treatments

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Research report from a financial institution detailing advancements in cancer therapy targets. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
paper, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
53 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    CITIC Securities: Unlocking Undruggable Targets, RAS Drugs Open a New Landscape for Cancer Treatment

    36氪获悉，中信建投证券研报称，解锁不可成药靶点，RAS药物打开肿瘤治疗新格局。RAS是人类肿瘤中最重要的致癌驱动基因家族之一，主要包括KRAS、NRAS和HRAS，其中KRAS占据核心地位。RAS靶向治疗已从G12C单点突破，进入G12D、Pan-KRAS和Pan-RAS(ON)多路线推进阶段，管线布局和临床验证正在逐步丰富。2026年ASCO大会上，RMC-6236在2L转移性胰腺癌III期研究中取得积极结果，中位OS较化疗接近翻倍，进一步强化了市场对RAS靶向治疗临床价值的期待。国内企业也在G12D、Pan-RAS、Pan-KRAS等多方向积极跟进…

RELATED ENTITIES

RELATED TOPICS